0001144204-11-042179.txt : 20110726 0001144204-11-042179.hdr.sgml : 20110726 20110726172201 ACCESSION NUMBER: 0001144204-11-042179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20110725 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110726 DATE AS OF CHANGE: 20110726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEPHROS INC CENTRAL INDEX KEY: 0001196298 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133971809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32288 FILM NUMBER: 11988085 BUSINESS ADDRESS: STREET 1: 41 GRAND AVENUE CITY: RIVER EDGE, STATE: NJ ZIP: 07661 BUSINESS PHONE: 201.343.5202 MAIL ADDRESS: STREET 1: 41 GRAND AVENUE CITY: RIVER EDGE, STATE: NJ ZIP: 07661 8-K 1 v229749_8-k.htm CURRENT REPORT Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 25, 2011

NEPHROS, INC.
(Exact name of registrant as specified in its charter)

Delaware
 (State or other jurisdiction of incorporation)

 001-32288
 
13-3971809
 (Commission File Number)
 
(IRS Employer ID Number)

41 Grand Avenue, River Edge, New Jersey
07661
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code (201) 343-5202

__________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 1.01.
Entry into a Material Definitive Agreement.
 
On July 25, 2011, Nephros, Inc. entered into a letter agreement with DHR International, Inc., an international executive search firm, whereby DHR International will conduct a search to recruit a chief executive officer for Nephros.
 
Under the agreement, Nephros will pay DHR International a retainer consisting of $100,000 in cash and equity worth $25,000.  The cash retainer is due in three equal installments.  The first retainer payment was due and paid on execution of the agreement.  The second retainer is due when Nephros begins the first round of interviews and the third retainer is due upon a candidate’s acceptance of an offer from Nephros.  The stock portion of the retainer is in the form of an option for 20,000 shares of common stock with an exercise price of $1.25 per share, which was the closing price of our common stock on July 25, 2011 as reported on the Over-the-Counter Bulletin Board.  The option is fully vested and has a term of 10 years.
 
In addition to the payments discussed above, Nephros will reimburse DHR International for indirect out-of-pocket expenses related to the executive search, such as administrative, database management and reproduction costs, which are estimated to run 12% of the aggregate retainer, and are payable in three equal installments to be billed at the same time as the three retainer installments.  Nephros also must reimburse DHR International for any direct out-of-pocket expenses, such as travel and lodging, which will be billed monthly as incurred.
 
In the event that Nephros hires a candidate provided by DHR International for any position other than chief executive officer, Nephros will be obligated to pay DHR International a fee equal to 33% of the individual’s projected first year total cash compensation.
 
DHR International anticipates the search to be completed in three months.  If the search is not completed by that time, DHR International will continue the search without charge for a period not to exceed six months.
 
Nephros may cancel the agreement at any time. If Nephros cancels within 60 days of execution of the agreement, the second and third cash retainers and the reimbursable indirect costs will be prorated through the date of cancellation.
 
If Nephros hires a candidate presented by DHR International and that individual is terminated, either voluntarily or involuntarily, within two years from the hiring date, DHR International will, at Nephros’ option, refill the position for no additional fee.
 
The description of the license agreement set forth above is not complete and is qualified in its entirety by reference to the agreement, which is attached as Exhibit 10.63 to this report and is incorporated by reference.
 
On July 26, 2011, Nephros issued a press release announcing, among other things, its entry into the letter agreement.  A copy of the press release is attached as Exhibit 99.1.
 
 
2

 

 
Item 2.02
Results of Operations and Financial Condition.
 
On July 26, 2011, Nephros issued a press release that reported, among other things, the amount of revenue Nephros has received for the first six months of 2011 from the Office of Naval Research for work related to an advanced water purification system for military field use that Nephros is developing using its proprietary dual stage cold sterilization ultrafilter as the basis of the portable system. For 2011, Nephros has generated approximately $249,000 of revenue through June 30 from its U.S. Defense Department project.  A copy of the press release is attached as Exhibit 99.1.
 
Item 8.01
Other Events.
 
On July 26, 2011, Nephros issued a press release that provided a corporate update on its operations and strategy.  A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.
 
 
(d)
Exhibits
 
Exhibit No.
Description

10.63
Letter agreement, dated June 27, 2011, between Nephros, Inc. and DHR International, Inc., entered into as of July 25, 2011.
   
99.1
Press release dated July 26, 2011.
 
 
3

 

 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Nephros, Inc.
 
       
       
 
By:
/s/ Gerald J. Kochanski
 
Dated:  July 26, 2011
 
Gerald J. Kochanski
 
   
Chief Financial Officer
 
 
 
 
 
 
 
 
 
 
 
 
 
4

 
EX-10.63 2 v229749_ex10-63.htm LETTER AGREEMENT Unassociated Document
Exhibit 10.63
 
 
CONFIDENTIAL

June 27, 2011


Paul Mieyal
Acting Chief Executive Officer
Nephros, Inc.
41 Grand Avenue
River Edge, NJ  07661

Dear Paul:

We are pleased to propose the arrangements under which DHR International will conduct a search to recruit a Chief Executive Officer who will report to James Scibetta, Chairman of the Board of Directors.

We are guided by your desire to have this individual located as quickly as possible.  Work on the assignment will begin immediately upon our receipt of a signed copy of this agreement.

 
Professional Retainer and Fees

Consistent with the standards of the retained executive search profession, our professional fees are non-contingent and non-refundable and are equal to one-third of the first year estimated total cash compensation; however, we will conduct this assignment at a fixed fee of $100,000 plus an additional fee of $25,000 being payable in equity.  Our fee is payable in three equal installments.  When we are retained, an invoice for the first installment will be payable upon receipt as a non-refundable initial retainer.  Invoices for the second and third installments would normally then be sent in thirty and sixty days and be payable upon receipt.  However, we agree that for this search that the second retainer would not be billed and due until Nephros initiates the first round of candidate interviews and that the third and final retainer would be billable upon the candidate’s acceptance of an offer from Nephros.  Also consistent with executive search practices, DHR International is reimbursed for search-related indirect out-of-pocket expenses which include allocated support expenses such as administrative, communications (voice and data), reproduction and report production, database management, and computer services, which historically have represented twelve percent of the applicable retainer.  These expenses are pro-rated and billed with the three retainers.  Any direct, out-of-pocket expenses such as candidate and consultant travel, lodging and video-conferencing will be billed on a monthly basis as incurred.

Additionally, if any candidate presented by DHR is employed by Nephros, Inc. or any affiliate for a position other than that called for by this assignment, you agree to pay DHR an amount equal to thirty three percent of each additional hire’s projected first year total cash compensation.
 
 
DHR International   |  Asia  |   Europe  |  North America  |  South America  |  www.dhrinternational.com
 
 

 

 
Duration/Scope
 
It is planned that this search assignment can be completed by the end of the traditional three-month retainer period.  Should this not occur, we will continue the search without charge for a period not to exceed six months.
 
Cancellation
 
DHR International recognizes that a client’s recruiting needs may change over time.  If you cancel the search by written confirmation within sixty days, we will forward a final statement for our professional services prorated through the date of cancellation, and for expenses related to the search.

Except as provided above, in no event shall you pay DHR less than the first retainer plus direct and indirect expenses.  It is further understood that our search will include the evaluation of any candidates who may have been or may be identified by you or others, or may be already employed by you, and that any and all such individuals shall be deemed candidates presented by us for purposes of this letter.

If the search is cancelled by either party, your obligations under this agreement, including but not limited to those described in “Professional Retainer and Fees” above, will survive.
 
Two-Year Guarantee

If the employment of a DHR placed executive is terminated (voluntarily or involuntarily) within two years from the hiring date with Nephros, Inc., we will, at your option, refill that position for no additional fee.

Confidentiality
 
DHR International will maintain the confidentiality of all proprietary and confidential information supplied by you, it being understood that proprietary and confidential information does not include, and this obligation will not apply to, any information (i) in the public domain, (ii) which is or comes into DHR’s possession without an obligation of confidentiality, or (iii) which is required by law or Nasdaq/securities exchange requirements to be disclosed.

General
 
This agreement constitutes the entire agreement between the parties with respect to the subject matter and supersedes any previous oral or written arrangements or understanding.  Equal Employment Opportunity is a federal law, and in providing services under this agreement, DHR International will adhere to all prohibitions on discrimination on the basis of race, color, religion, national origin, disability or handicap, sex, age, marital status, sexual orientation, or military veteran’s status.
 
 
DHR International   |  Asia  |   Europe  |  North America  |  South America  |  www.dhrinternational.com
 
 

 

 
It is DHR International’s standard policy to commence work on any search assignment only after written confirmation of the Agreement has been received by DHR.  If you are in agreement with the terms and conditions as stated above, please sign and return a copy of this letter to me as our formal authorization to proceed.

We look forward to the opportunity of working with you and sincerely hope that you select DHR International to conduct this important assignment.

Best regards,

DHR International, Inc.



Donald Kilinski
Managing Director

DK/lk


Accepted:

/s/ Paul  Mieyal
Paul Mieyal
Acting Chief Executive Officer
Nephros, Inc.

7/25/11
Date
 
 
DHR International   |  Asia  |   Europe  |  North America  |  South America  |  www.dhrinternational.com
 
 

 
GRAPHIC 3 logo1.jpg GRAPHIC begin 644 logo1.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_ MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L M(QP<*#7J#A(6&AXB)BI*3E)66EYB9 MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+ M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1 MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15 M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W M^/GZ_]H`#`,!``(1`Q$`/P#W^BD)I,T`.HK/U;6;+1-,GU"_E\JV@7<[D=!7 M#:C\8],TZ*VFET+5_LUVA>"?;%ME4=U._G^=.,7+8ESBMV>DYHK%\/\`B6U\ M1Z)#JMM!^:UPV3T-3?H4G?8?17/ZKXCNM-N9(D\-: MO?1H`?.M%B96^@,@;CZ5QI^.WAU20VDZR&!(*F*+((ZC_6=:M0E+9$.I&.[/ M4J*X"W^*<5W&)+?PCXHD0]&6R3'_`*'4TCW/0Z*YK2O'_A?6YHX+'6+=YY/NQ.2C$^@#8KHMV!D"HV*33U0 M^BN4UOQI)H(N9;CPSK=E5=)UEF8X"K' M$23_`-_*I0DU=$NI%.S9ZE16+HNNW&KR,)=!U/3D"!E>\$8#9[`*['/?D"K6 MJZE-IMJ)H=,N]0_\`K.15W1OB=%X@A>;2O"^O742-M9T2$*#Z9,HYJG"25VB5 M4BW:YWE%9VIZE-I]JDT.EWE^[,%,-MLWK[G>RC'XUP^H_&72=)OGLM0T'7+: MY0`M')%$"`>A_P!92C%RV'*<8[L])HKSNQ^+EEJ2;['PQXDN4_OQ6J,OY[\4 MDGQET"TNQ;:EIVLZ=*1G;=6H!Q]`Q)I^SEV)]K#N>BYHK&T+Q3HWB2%Y-)OH M[G9C>HR&3/J#R*V`U0:)WU0M%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`-/2O)?BE\2)]'F.@Z',([W&;JY7DP@CA5_P!H]<]OQKUB5Q'$SG.%&>*\ M'\4^"K>'Q_>:AKS7L.B7:-=&XM8FE*2<91B`<` M#M3OI=2C33]-;4M?>Y5Q>7LK3)##P""#G`)ZOV%=W>?#6X\0V^@N\9LXOM$L MU_8F;_4+*076(C.1N0D=\..>*[+P?X5TWPKI4L=@K2?:?WOVAE)9U;[H)QV' MIQSFNCD\MA*"O7"#*_Y]:56LE+W-!4Z/N^^>=>,?%C>&8[O2XY6TB+['%_9T MD-JLI))8,%7(`&-@]L9[UYQX<^(5YX8UTW$-Q>W>ES%?M4-Y,9'0'LV< MGW&!SVN^-O$>DQ?$6^NH=.&J+`/(:.]E)A60<,40<8Q@9]03V%86L7WA[6HR MND:%=6.HG#;GO-Z.1]X;('&,?2NJG!*.JW.>I4UT>Q]1P31W$*3P2+)%( MH='4Y#`C(-?*VNQK#\1-1C0`*NK/@#_KJ:]Q^$=V)_!<<,5[)>002E89)+9H M2$Z[>20<'(R"1V[5XAXA_P"2DZG_`-A=_P#T8:RI*W.D^A==\T8L^K!D]ZK7 M^GV>IVC6M_;0W-N_WHYD#+^1[^]6A2US1V1V,^=/B5\./^$5*:KI>]M*D?#* M3EK9^W/=3V/4'ZUVGPH^($VLAM"U>7?>PIN@G8\S(.Q]Q7HNO:9#K&A7VG3( M'2X@=,'L2.#^!P?PKY,TC4Y]'U2TU*!MD]NXD_Q%=3_>TVWNCCG^YFG'9GUQ MJ:+)I-ZC#*M!(I^FTU\J^"U5_%NB!@"#=1Y'XU]43S+?!?_`))]#_UWD_G6]5_N MH(XZ?\>1Z#MKP#XZ1A?%M@P`W/9#=[X=J^@:\!^.W_(U:;_UX_\`LYHP]NI/0"L(MWTWO^II%+D5SY4T M[4+_`,(>*/.A=H[JQN&AE46-MFIAA;Z]BW1116)UA1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`5[W_`(\Y M<8^[WK-U"6YCTN]-C"D][Y+&..3H[@$8/MTXK7=0R$'D'C%9B$X\H?P\-GGG MIC\>:QF[23':Z/F"R\1^)/#VI-+%?WUK=(V)8)78KQ_"T;<8'IV[5[I\./%V MJ>+M,N[S4;>"-(K@1QM`"-Q"Y;()^G2O-/&?A:\U?XMR:9`?*?4`DR33.2I7 M;\S`^VT\>PKW+3],M-,TV"QL46&VAC$:JJC&,\DCU./UKLKSCR*RU9QT(SYF M[Z(\>\6?".^6ZU/6--U"W>T*R7C0W`99022Q1<#!X[DCTKRN,-*ZK$K.[D!0 MH^9B>@'N?ZU]=7:?:;6>"=05E1ES_=R".1[#O7SOX+\$:M>^*Y+:6%K;^RRQ MDED!"B5?N#/?+;3QV&?2KP]=N+YGL17HKF7*>[^#=*O=&T:VLM1NGNKY8MT\ MKN7.]F)(!/8$D?A7SMXA_P"2DZG_`-A=_P#T8:^G=)MA;64:+)+(JJJ(\SEW M90,`LQY)/4FOF+Q#_P`E)U/_`+"[_P#HPUG0=XS?=,O$JRBCZM'2EI!TI:PC MLCK$8CK7QE>$-+:?[J+R3^E=5'W82D]CCQ.LHI'T]IZLG@NW5_O"P`.? M^N=?+?AJ&ZGU_3(K*Y%M=/,JQ3E=WEMV.*^L[Q`FE7**`%6!@!Z?*:^5O!/_ M`"-^A_\`7U'447:C/T#$+WH(]L_X1+XC?]#]%_X`BC_A$OB/C_D?HO\`P"%> MDBD:I]HSH]FCYF^)NG:YINN6<6O:PFJ7+6VY)5A$>U-Q&W`Z\Y->L?!?_DGT M/_7>3^=<'\=O^1LTW_KQ_P#9VKO/@O\`\D^A_P"OB3^=:5OX<#GI*U>1Z'7@ M/QV_Y&O3?^O+_P!G->_5X#\=O^1JTW_KQ_\`9S1A_P"(:8K^&RSX(E\>V_@0 MS^'ETJ2RC,C+'*&,[$'D`8P3Z17M/P=_Y)[;_P#7:3^=<=\8O`XMI7\4:=%^XE;%]&H^ZQX$OT/0^Y![ MFE2DFW'9ZZ_,SJ0ER*2/1O!G@C1O"EH9+#_2)YE&Z[?!9E[!2.B^PKJP1BO) M/@QXN%YI[^'+V?-S;#=:ACUB_NCUV_RKULT)E,L9PS# M##IN_P`#5=KS6`[!-*@902`3>8R.QQLXI/M>M?\`0(M__`W_`.PI2BI*S%

H0DHK1-&Y4,,`C^@JS,VJ7" MXET2U?ZWO_V%5OLE^)-Z:+`K=BM]T_\`'*Y94:M_=>@TTB\DC``'H%(P<<@:Q+C^5=M.4 M8II]3GK0E.UCOK;7]'NXP]OJMC*OJMPI_K69K?C[PUH,)>[U6!Y`,B&W;S9& M^@']<"N3/PIT$]?"2?\`@WD_PJW:?#?0[-@T?@JR=@ M9YQXD\5Z]\4M2@TW2M.E2SC?*VZ-N!;L\C`8&!^`]Z]6\`?#ZV\&VLDLDRW6 MHSJ%DG5<*J_W5SVS^=;5HE_80"&S\/6-M$.B0W01?R"5.;O6<8_L>W_\#?\` M["B4N9PZ?X?U"[N'5(H[=V+,O<=8\.V>NRZE<:CH5W=?9W+2P_VS+LW!0WR)]WH1Z3Y@0>.1UXP0<8-7!Q4)1?4SJPE.2:Z'K*.&4,I#*W(( M/!%!.3TKA_#FGOH<,\^GZ)7_&V\@NO&=K%'(K-;V820`YVDLQ MQ^6*[WX*7,'KVVN+Q?"KR&-W$F[5Y"S,O7G M^+TSFI](\$:/)$+O2=#F@65%820ZY/$QSG@X&01T(/3I6LW&45'L80A)5'/N M>I;LBOGKXW7L-UXSMK>)U9[:T"2X.=K%B)+&2`:?(8[:8HQMM5 M>!]ZC&-R@$CGN<'K7*GP#H+V-QJ61I-7%L!L;2WR9QTR>W?C)&3BKW15-VCRR/"O&'AR[^'7BZ"73[B18BWVBREYRH M!^X3WQT/J"*]G\$_$;3O%EHL4C1VFJ(,26SN/F/]Y#W'ZT>(;-/$FBM_;'AZ M&:UMW:1?]/(=2I(.TJN><'C/-A%: M3<9I7W,XQE"3<=CUK)I6923^)JY]KUK M_H$6_P#X&_\`V%969T7-:BLG[9K7_0(M_P#P-_\`L*/MFM?]`BW_`/`W_P"P MHU"YK45D_;-:_P"@1;_^!O\`]A1]LUK_`*!%O_X&_P#V%&H7-:BLG[9K7_0( MM_\`P-_^PH^V:U_T"+?_`,#?_L*-0N:U%9/VS6O^@1;_`/@;_P#84?;-:_Z! M%O\`^!O_`-A1J%S6HK)^V:U_T"+?_P`#?_L*/MFM?]`BW_\``W_["C4+FM16 M3]LUK_H$6_\`X&__`&%'VS6O^@1;_P#@;_\`84:AQ:]8:?;F$)+996T_*PP!M0F ML+T-EO+>-'8E3W!V#_OH>AJ.X\5WD=AJ]Y%]E>.RU*"SC.QOG60P_,>>H\[_ M`,=I/['U2*;3GMK&&+['=27;DW08SR2!EFF.]/?Q9IBX&Z8N9DA M\M8BS!G4LG`[$#K^!Q@U@1>&M12TM[62S62&.RDL9%-TH,D;G/!V_*15I]+U MN2*R26WA>2UGCG$BS(N_8"`#A.^X\_H*&D";-:'Q5I\UZMH!.DC3K;_O(2H$ MC1"55.>A*'\^*@U'Q=:6FGWT\,,LLUI;BY\EE*&2,L1N&>V5(K,FT/5I-4DO MOLL:L^H1W^P70P&2$0[<[.A49^M57\+:F]O=121F1[BR-D96NEW;2Y8.3LY? M+'GO[46079T1UV&'6+FVFFDW!8%BMO(^;<^\C#9^;(1O3&TTLWBO3H(UUC^T?N2FVY`"M&)!G&WD,)7!'H1BHW MT#4WVD6D8)CN5D)N@2[3_>;[G'L*=D',SI/[>L6NK>W#R9N2$BD\L[&8H7`S MZE1G_P"O4?AG4+C4]#CNKHJ9C+*A*K@';(RCCZ`5S\6@:O'=VL[0K)]FEBE0 M/=`X*1>7M!V9"D$G`_B8FM+1;?6-'TU;--/BF59)'W/=@'YW+$<)CJU)I`F[ MG2YI:R?M>M_]`BW_`/`W_P"PH^V:U_T"+?\`\#?_`+"ILRKFM163]LUK_H$6 M_P#X&_\`V%'VS6O^@1;_`/@;_P#84:AGKQCGFE6Q@B\T1PA#,`)&3@M@8R3ZXJW2T#L4H-/M[:9Y MH8BCLJHV&."%^[P3C('&>M#6$#64ED8R;=T9&3<>0V]:T%Q^^5F4@J=NY0"PW8VD@$9&?Y&BP% M^L+4KN9=?@M&N6M+1K624S`@;G!`QE@1P"3[_A6AF?D!Q_M<=*N)K,VH^&[Z\,JZ?M@$L5PCH^S*;AD'(!!X(/! M_&MYH[9FWE8BV1\Q`SD=*:$M/*D0)#Y1^9U`&TY[D47"QRT?B&^MKMX;H.UR MK0VS(0HAWMO(F5L`[651WX)QUJRWBFXCN1;36`2=S&(\/N4>8F8\L.,%U=,C MIMST(KHG2W<>4ZQ,&&-A`.0.>E5TO[5KZZM`A\VUBCE?"@@HQ;:1CT*/QUX] MZ=Q&"WBV5FVP1VCLTT,<9,C!2))'3TSP5].Y%2>'M3DDO]0L9)3)+%<3,!)( MS$_,/E1CU53G([97BM/3]1TC4]S6AB8[%G^>`QG:Q.U\,!D$AL'U!JXYMX4: M98T+*&<*H&XG&3CW(HN@L^YS%MKDZ:-::K->M),^$N++"`1NSJG/`*A">>>E M2GQ3=IJ<=I);VR%S`IQ-N(:4S`8QP>8@?HV.U;MK-8WEFEW%''Y=U&LAW(`6 M4@?>!_+FIC%;#&(X,CIP.-O3'T_2BZ"SZ',Z9XHO+NWL(VB@EN)+:.>9Q($' MS,ZG`)Y*[>0,GGMQ6]H-]<:EI4%[<1P)YZB2-87+#:0",Y'7.?TIM_[%M M*AFM\R+>1A<'8@GE,@8=\KG'O37\+W%M/<7:2-<2E)5;$FU[A&3:JD'Y`PP/ MGQDXYZFNPVBC:/2GS,GE1RQT:^O?#&IZ8?+B\^5A;,Z*A\OY<%P@`SD-T&<; M<\YJ&[\+W\MA<6$%S;B%VG9)75C*/,&06;^(ALC=]XC'.0<]?M%&!1=CLQ`Z5##X3NX);>19[<+$%+Q*&"S%9 M6E%V'*CD$\*7BO;L+J(M$UN1*0=X"2.S`'Z/M'L!FK MFBZ%=Z;/,\LENV^RAMLH&RS1F0[VSW82#/TKH]HIC_*#C''J>*+ARHY"P\)7 MUI':A[J`B!8-\"@^7,T>[)8GD?>X'3*@FG6OA6]M+R.9+N"508V;S`P(*QRH M0/;]XN/]WFG_`/"7,-*TR%)1OPJH\PC)7N3UX]CFLP^(]0@CBU*1 MHW>"WOFF@\PJKK%(`!@?Q8!`X[^]5J0^78T+3P?(L$EO?3+,CPA%=793$?)6 M,A0.,97<,]"3QGFIW\/:@]_8W+75L3`$:9O+VM+)^\\P]^#Y@(';!SGC%SQ5 M=S66@O/;SM%()H$5D(!PTJJ1S[$UEOJ%YINMJCF61YXXE,- M')V(KERI"%6Z$-T/3M5GS$`)WK@'!.>E&_#'O5O3-&U31V8QR6EQYTX9]X(,:&5F8*W7&UB0#_`!9[ M-P607=RY?7FBJTUE=*`UF$O&A6)@0%;723,8?)0*@7Y=[-D_@P&/;/>C0#0E>U++#,T)9N5CHSR_:`(KB6VE?=DM'Y+;MJ^S=_JU1'P\72 M":VM;2VD%Y',4V!=L<9.U1@=<9/_``(T#-SS;+,F9+?,2[7Y7Y!Z'T%30M$T M*&!D,1'RE"-I'MBN7/A:\CAB6&:VD>VBD2$7"L5D+2K(&DQZ;<]\GFMK0["7 M3M-2"=8EEWN[^4[,&+,6)R0#R2:&E8$V:5%%%(84444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44UW$<;.< MX4$G`R:S-,UZVU622.&*ZC,9*DSP%!D=5R>_MUHL*YJTE0SW4-K&))YHX4)" MAI&"C)Z#)[U"=4LEG>%[VV$J`EHS*H8`#)R,YX'-`R[1587MN;7[4+F$V^W= MYV\;,>N8_EIME4[F_NCGKR.*!%P@F@<5!%>03R2QPW$ M4DD1PZ(X)0^X'2FS:A:6X8SW<$04[27D5<'&<<]\,!3W)["I89DGC62-U>-AE64Y!'J"*`)****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****``]*P;32 M+F'SO--E+OU%KM=\;'8I].?OCUZ>U;IZ&N7MM1U)]1U\1'1'`:)`JVS7!+M_K=I&8HS MQE\'(_ER2%_M#6A-/&UM9%8@&9XG>0H#DC*X&YL`':#GYA[9%<6@W3-&:'2R MM["TKK).XMV<;90TC,ID7[I8)"R M]PP((!&>V>F:T8M7O+S3();6TC%P\2RLTS'R$'\0#J#DCGC%9R^*[B"[MX+N MTACDE:!0BLV9!*6`="0,JOR[N.,GI@;GJ%E8MV7A^X6^GFNVMHT=/+B-D7B9 M4W%@O7&.23W)/I@4LF@R?:M3D,5M(+^9&1BF6@_=A&R2PM#!"&M7A1%.286+`/Z@YQZC`-:FD6!TZWDC>3 M>\DTD[8&`I=BQ`]AFLB\\175C-,L]M#M$8D4AFPBF54WDXPR[6WDC[H&#GK6 MIH>I?VK9O<87Y)I(=T9RC[&(W+['&?Q[]:3N"MM6:*`*T]E#<%!*"40@[,X4XZ9'?%1R:9;R M`??4B8SAD6I(X]/Q[^N:DELH9 MIXYI07:/)0$Y5201G'3."1FK%%`6*=II=AIX<65E;6P?&_R(53=CIG`YJ";0 M=.G##[,D:N'618OD$@;&X,!C.<=^:TZ*`,Z+1+*&;S8T99%1T1MYS&K'+!?3 G)Q^56[:UBM(5AA0)&O11^9/U)Y-3447%8****!A1110`4444`?_9 ` end GRAPHIC 4 logo2.jpg GRAPHIC begin 644 logo2.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_ MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L M(QP<*#7J#A(6&AXB)BI*3E)66EYB9 MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+ M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1 MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15 M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W M^/GZ_]H`#`,!``(1`Q$`/P#W^BD)Q2;O:@!U&:SM7UJRT/3)]1OY/*M8%W.Y M'Y5PNH_&/3].BM9Y=`U7[->(7MY\Q;95'4J0Y_+K347+8ESBMSTO-%8GA_Q+ M;>(]$AU:WM[F&"8$JLZ`-@'!/!(Q[UL!\G&T_E2VT&FF/HKG]4\17NG7,L<7 MAK5;Z)`#YUKY15OH"X;CZ5Q;?'?05)5M'U<,"05*1Y!'4??ZU2A)[$NI%;L] M4HK@+;XH?;(Q);^#?$\B'HPM%Q_Z'44OQCT.QN%@U;2]:TR1N0MU:;<_3!.? MPHY)![2/<]$HKF-*^(/A;6IXX++6(&GD^[#)E&)]`&`KI-_&0*GR*33V'YHK MD];\9SZ$+F:?PQK$]I!DFY@$3(5'\0&_./PKEU^.^@NRJFCZN[,<*JK$23_W MW5*$FKHEU(K1L]4HK$T;7;K5I&$V@:CIR!`RO=^7\V>P"N2#WYQ5K5=2GTZV M$MOIEUJ#EPOE6Q0,!@_-\[*,<>O>E8JZW-'(]:,UYIJ7QET[1[UK/4?#VM6U MRH!,N,F09--PDM63[2+=K MG>TE9^IZE<6%JDUOI=U?NS`&&W*!E'J=[`8_&N&U'XRZ;I%\]EJ/A_6K:Y0` MM'(D6<'H?O\`2B,7+8DTM>=6/Q:MM30O8>%?$5R@XWQ6R,OY[\4DGQ MDT.SNQ:ZGI>M:=,1D+C>)8GDTF^2X M\O'F(`5=,^JGFM@-Q4&F^HZBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`&M]VO(OBE\1[C29CH&B3".\`S=W*\F'(X1?]KN3VX]:];F<1Q,YSA1GBO" MO%/@B"#QY>ZEKBWXT.ZC:[::RB,ACDXW*V,D`\8UN?EM$YCP7 MJ%])JD::7IGV_7VN5D^WWKYSBN]O/AK-X@AT-Y4%HGVB6; M4+'SL^4LI!=8F'4%D+#OA^O%=GX1\,:=X6TF2+3D=TN3YWGNOS,&^Z"?8>F/ MI70R%&$H*'YL(,K_`)]:56LN;W585.B^7WCSCQGXK?PTEUIBROI$+6<7]GRP M6RRDG+!PJY``QL'MC/\`%7F_ASQ_=^%]=:YMI;RYTR8K]I@NYC(\AP`\@/9B M-/$NEP_$2_O+;3(]1\G]PRWDA,0D'RN40<#CC)[Y/I6+J^I:#KD9 M32O#TNGZD?F$C7Q=9#W&TC[Q`X/K773II1]Y;G/4J7>CV/J&VGBNH$N()%DA MD571U.0RD9!_(U\KZZBQ?$748T&U5U9\`?\`70U[A\(KD2^"HX8KR:ZMX96$ M$DMJ82$Z[1\S!L'/(..W:O$?$/\`R4G4_P#L+O\`^C#6--?$O(TKR;46?58R M>]07UC:ZA:/;7UO%<6[_`'HYE#*?P-6%I:YH[(ZSYV^)?PX'A<+JVE;VTJ1\ M21DY:V<],'NI['J#]:[#X3^/YM7SH.KR^9=Q)NMYV/S2H.H/N*])UW38=7T2 M]TZ9`R7$#1D'L2.#^?/X5\E:3J4^D:G::C"VR>V<2#Z@\BNFWM*;ONCCF_93 M3CLSZYU.-9-)O$;E6@D4_3::^5?!:J_BW1`P!!NH_P"=?4\\ZW.ARSK]V6U+ MC\4S7RUX)_Y&_0_^OJ.IAK1F_(>(^.)]9!1DFE(I1WH-8Z'6>`?'1%3Q9IQ` M'S6(S^#M7>?!A!_P@$;`?,UQ(2?QKA?CKSXKTW_KQ_\`:C5WGP7_`.2?0_\` M7>3^==%7^'`XZ?\`'D>@;>M>`_'2-5\6V#`^FY MI'X%<^5;"^OO"/BCSH6,=W87#0R@6%MB!W+$Y]`#7U=8VJV6GVUJA^6")8P?8#'] M*VQ+7.K=C#"WU[%NBBBLCK"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`KWO M_'I+C'W>]9E_)=1Z;>'3XTDOO*8Q+)]UG`(`)].G%;#@,A!&0>U9B$D>2#]W MAN_/3'X\UC-V=Q]#Y=M-9\0^&]4DDCNKVROD;$T,A8<_W60\$>V/I7NOPU\6 M:MXLTN[O=3CMU2*X$<30(5W87+$Y)S_#TKSCQGX5NM6^+CZ9$P@_M)5F2>5B M04V_,P]_E/'TKW"QL+6PTZ"RM%$5M#$(E5<8QGGCWQ^M=E>I'D5EJSDH0ESO M70\B\6?".X6XU36-.U.+[,5DO&M[A"'!.6**1Q],\]O>O)XE:9T2)&=Y"%11 MU8GH/KT_.OKJZ3[1;S0S@%)$8$_W<@@DCV%?/?@SP'J]WXIEM[B)K5=++;IY M%(4R@?(`>_.UN.PJL/7O%\SV,Z]%Y^#]*N]%T>WLK^[>\O5BW3S2,6) M=B21DGD`Y'X5\[>(?^2DZG_V%W_]&&OIW2+9+6QC2,R-&JJB&1RS%0,#)/)/ MO7S%XAY^).I_]A=__1AJ*#NIONF7B%911]6+TI:!2UA'9'6,8C'6OC2[(:6Y M*"X$<886`!'_`&SKY<\-07-SKVF0 M6EU]EN))D6.<+N\L^N.]?65Z@32[E5X40.`/^`U\K^"?^1OT/_KZCJ*+M2EZ M!B%[T4>VCP3X[_Z*+)_X`#_XNE_X0GQWC_DHTG_@`/\`XNO1P*1JGVDCH]G$ M^9?B;I6L:1KEG#K.MG5IWMMZ3&#R]B[B-N,G/3^=<)\= MO^1KTW_KQ_\`9VKN_@O_`,D^A_Z[R?SK2L[P@<])6K-'H=>`_';_`)&O3?\` MKR_]G:O?J\!^.W_(UZ=_UY?^SFC#_&:8K^&RSX('CR/P(;CP[-IAM$:1DADC M+3,P/(';Z5PUSK5]XJURV@\4ZS=PP+*59FC!%NW0YCX`/8\9'YU[9\'>?AY! MQ_RVD_G7)?&+P0(F?Q1I\9\MSB^C4=#T$O\`('Z@^M*G)-N.VYE4A+D4D>B> M#/!NB^%K(MIG[^2=06NW(9I%[8(Z+["NI!`'6O(/@OXM%Q9OX:O)OW\`WVH8 M]8^ZCZ?RKUX#C-8--.TMSIIM.*<1]%%%,T"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHI,T`+129I:`"BDS2T`%%%%`!1103B@`HI-U+0`444@ M.:`%HHHH`****`"BBB@!N,C%5)[3=(9$.&(PP/1O\*K&YUO<0FFV;`$@%KY@ M2.Q_U7%)]IUW_H%V'_@P;_XU2E%-68KF+JEK"VI:?J-P7-SISR,%./F5UVL" M#VX'2KD>H1LT:O`8W90RD<_0YJW*VLS+MDTC3V'O?M_\:JM]DU+S"ZZ-8*WJ MNH,/_:503VI\<#7*$-O2(D8!ZMZ_0565-65M_P#8 M^GL_]YK]B?\`T54OGZ[_`-`NP_\`!@W_`,:K2-%_:8.1HG;!$68A449+,<`` M?TKY.U6^@O/&M[J"./L\NI/,K]MOF9!_*O?=<\)/KSSRWNAV,L\JX_>:M/Y6 M0,#*!`"/6L]/AKI14;_".F;L';M-T M&NZ8X[C[4@(_`G-9NM?$GPMHL#/)JD-U*!D0V9$K'\1P/Q-8A^&6CM][P=II M^NJ2_P#QNK5KX!TNS8-%X+T4L#G,EZ[_`/H49J5&"+;F>7:YXB\1_%C4X+/3 M=-9+.!LK#$Y=%)XWR/@#./R[9ZUZYX"\`VG@RRD83_:KZX`$MQLVC`Z*HR>/ MYULPG5[>%88-&TV*)>%1+YE4?0"&I#<:YC_D%6!_[B#?_&J)2'=0O+F1(XH[=R68XR=IP/QKY8\+74=AXFTFXN&"1PW*%V;@*,]Z M]RU3PY9ZS<:G=W_AB"[DMG+2*VK2D,VP-\JE,#J!VYJI9^!=!U"(R6WA'3W0 M*#DZG*"QSQA)5'/N>H; MB1T[5\\_&N_AO/&D%O"ZLUK:B.7:<[6+$X^N#7JLYG\3V,EN^E6\L5M,5Q'J MLD3;E&,@K&"00>"3SUKG?^$'T4:;/J,G@RS1(U>5P=4D+M@$L?N=PZ`\@'D''I7HDT4=Q#)#,BO'(I5T89#`\$ M&O-AX'TJR,$L/A2TCGN/EC$.KRJ[?*6(R$'8'O72OXAO[?1[745TRU:SE$>U MUOG.U6'#']UG`[GM^=9N*O=%4W:/*SP_QMX9G^'WBNVFTZ:46\C?:+*3!!3! MYCSWQ^H(KU[P1\3-/\46Z6]VT-EJ@^5H'?Y93ZH3C.?3K]:L:W;OX@T-SJGA M^PNK2)VD53J#9RI(!7;%W[<\YKGI/`OA[^QQJ8\(:=);-$LJE=3ER5.,?\L_ M>M)M32ON1&$H2;CL>JACG%+FN>TVUU/2=/BLK/2+)((AA%;4I&('7J8B:M_: M=>_Z!=A_X,&_^-5EJ;W-;-&:ROM.O?\`0+L/_!@W_P`:H^TZ]_T"[#_P8-_\ M:HU"YJYHS65]IU[_`*!=A_X,&_\`C5'VG7O^@78?^#!O_C5&H7-7-&:ROM.O M?]`NP_\`!@W_`,:H^TZ]_P!`NP_\&#?_`!JC4+FKFC-97VG7O^@78?\`@P;_ M`.-4?:=>_P"@78?^#!O_`(U1J%S5S1FLK[3KW_0+L/\`P8-_\:H^TZ]_T"[# M_P`&#?\`QJC4+FKFC-97VG7O^@78?^#!O_C5'VG7O^@78?\`@P;_`.-4:A_Z!=A_X M,&_^-4?:=>_Z!=A_X,&_^-4:A_Z!=A_X,&_^-4:A_Z!=A M_P"#!O\`XU1]IU[_`*!=A_X,&_\`C5&H7-7-&:ROM.O?]`NP_P#!@W_QJC[3 MKW_0+L/_``8-_P#&J-0N:N:,UE?:=>_Z!=A_X,&_^-4?:=>_Z!=A_P"#!O\` MXU1J%S5S1FLK[3KW_0+L/_!@W_QJC[3KW_0+L/\`P8-_\:HU"YJYHS65]IU[ M_H%V'_@P;_XU1]IU[_H%V'_@P;_XU1J%S5S1FLK[3KW_`$"[#_P8-_\`&J/M M.O?]`NP_\&#?_&J-0N:N:,UE?:=>_P"@78?^#!O_`(U1]IU[_H%V'_@P;_XU M1J%S5S1FLK[3KW_0+L/_``8-_P#&J/M&O?\`0+L/_!@W_P`:HU"YJD\45E?: M->_Z!=A_X'M_\:H^TZ[_`-`NP_\``]O_`(U1J%S5HS63]JUW/_(+L/K]O;_X MU1]KUS_H%V6?^O\`;_XU3`ULTM9'VK7?^@98?^![?_&J/M6NY_Y!=A_X'M_\ M:HL%S7HK)^U:[_T"K'_P/;_XU1]JUW/_`""[#_P/;_XU2"YK4=:R?M6NC_F% MV/\`X'M_\:I#=ZX.FEV/_@>W_P`:HL%S7QBBLC[7KO\`T"[#_P`#V_\`C5`N M]=/_`#"[#G_I_;_XU3L%S7I.E97VK74,7)S+@GYN,?R`IT=K%#+++'$JR2D&1U`RY`P"3WXXY MJS10%BLMK$L+PB/]VY8L/7<3G^9J%=+M18O9F+=;O'Y;(S$@KC&WD],<5?HH MN*Q2CL(8XYD6/:LQ+2`=R1@G_./6G?8X5\P+"H\U0LA48+`#`R>_'%6J!UH" MQ4BL8()FFBA"R,JHQ'=5^Z.O;-#6,+6CVAB!MW5D9,\$'.1U]S5RB@+%1[** M6)(G3*)]WDY'&.N<].*7['$L<4:1*J1$%%7@+CI^56J*`L4DT^WBACAB@6.* M)MZ(GRJISG@#W-(-,M5LY+,0`6\A8M&"<$L2Q_4YJ]24:AH000B&-8T4A1ZD MD_K4XZ4M%`PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"DI M:8Y(H`?2$`CFF=\4X4`*.E+33VIPZ4`%(>E+10`P(-Q/K[T[`I:3OTH`"H-` 3&*6B@`HHHH`****`"BBB@#__V3\_ ` end EX-99.1 5 v229749_ex99-1.htm PRESS RELEASE Unassociated Document

Exhibit 99.1
 
Nephros Provides Corporate Update

RIVER EDGE, NJ – July 26, 2011 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today provided an update on its operations and strategy.

“Nephros has undergone significant changes in its operational activities this year. The company is providing shareholders with an overview of these changes and the company’s ongoing strategy,” said Dr. Paul Mieyal, acting CEO of Nephros.

Recent Highlights

 
·
Completed $3,200,000 Rights Offering;
 
·
Completed Licensing Agreement with Bellco S.r.l.;
 
·
Received first installment payment of €500,000 from Bellco S.r.l.;
 
·
Obtained U.S. FDA 510(k) approval for MSU, SSU;
 
·
Obtained approval to market Dual Stage Ultrafilters (DSU) in Canada; and
 
·
Engaged DHR International for CEO recruitment

Hemodiafiltration System

Nephros anticipates submitting a new 510(k) application to market its leading-edge hemodiafiltration (HDF) system for end-stage renal disease (ESRD) in the U.S. in the third quarter of 2011 which would be subject to the FDA’s standard 90-day review period.  The application will detail Nephros’s OLpur MD220 diafilter and Nephros’s OLpur H2H Hemodiafiltration module. Nephros’s OLpur MD220 is a dialyzer designed expressly for HDF therapy that employs Nephros’s proprietary Mid-Dilution diafiltration technology. Nephros’s OLpur H2H Hemodiafiltration module enables the most common types of standard dialysis machines to perform HDF therapy. Nephros believes that, if approved, its technology would be the first approved on-line HDF therapy available in the U.S.

"Physician interest in Nephros ESRD products continues to be strong; I look forward to the new 510(k) submission for FDA approval of Nephros’s products as a significant step toward bringing this important HDF therapy to the U.S.,” said Dr. Leonard Stern, Medical Director for Home Therapies at Columbia University Dialysis Center and clinical advisor to Nephros.

Ultrafiltration Products

The Association for the Advancement of Medical Instruments’ (AAMI) adoption of more stringent water purity standards for dialysis applications as well as observational studies showing a significant reduction in required erythropoietin dosing when the Nephros DSU is utilized during dialysis therapy has significantly increased interest in Nephros ultrafiltration products. In addition to the DSU, Nephros recently announced 510(k) clearance for its SSU and MSU filters to enable these additional ultrafiltration products to be used in dialysis applications.
 
 
 

 

 
Nephros has introduced product line extensions for the hospital infection control market which include a more durable filter design to withstand the higher pressures of hospital plumbing, filter covers to improve the aesthetics of the filters in hospital showers, and the Safe Spout as a convenient endpoint filter to address acute outbreak scenarios.  Nephros is investigating a range of additional commercial, industrial, and military opportunities for its DSU technology.

Military

Nephros has contracted with the Office of Naval Research to develop an advanced water purification system for military field use. Nephros's proprietary dual stage cold sterilization ultrafilter will form the basis of the portable system. For 2011, Nephros has generated approximately $249,000 of revenue through June 30 from its U.S. Defense Department project.

In response to a Request For Information (RFI) from the U.S. Army, Nephros submitted its UF-40 ultrafilter for consideration as part of the standard issue hydration pack for soldiers in the field.  Nephros has been informed by the U.S. Army Public Health Command that its UF-40 filter has been validated to meet the military’s NSF P248 standard for emergency military operations as a microbiological water purifier.  Nephros believes that its UF-40 filter is the only stand-alone filter to date to have met the performance criteria of the NSF P248 standard without secondary disinfection steps.  The Army has not to date issued a Request For Proposal (RFP), and Nephros has no information regarding when or if an RFP applicable to the UF-40 ultrafilter may be put forth by the U.S. Army.

Business Development

As previously announced, Nephros licensed its mid-dilution technology to Bellco S.r.l. in exchange for upfront cash payments and royalties on future sales of MD190 and MD220 dialysis filters in Canada and certain European countries.  For the second half of 2011 and for the remainder of the license period, installment payments from the Bellco license will be recognized as revenue on an amortized basis.

During 2010, Nephros completed the initial milestone under the joint collaboration agreement with STERIS Corporation and expects to complete the remaining product development milestones under the agreement by the end of the third quarter of 2011.  The remaining milestones, if met, would result in aggregate payments to Nephros of $60,000.

Executive Recruitment

Nephros has engaged DHR International to recruit a full-time Chief Executive Officer.  DHR is the fifth largest search firm in the United States and the sixth largest globally.  The terms of the engagement are reported separately in a current report on Form 8-K filed with the SEC.

“Nephros’s Board of Directors thanks Dr. Mieyal for his continued stewardship of the company during this period,” said James S. Scibetta, Chairman of Nephros.  “The company believes it is now well positioned to attract top talent for its future growth. We look forward to working with DHR to identify a permanent CEO who can continue to maximize the value of the company for shareholders.”
 
 
DHR Contact:
 
Donald M. Kilinski
EVP and Global CFO Practice Group Leader
DHR International
One Newark Center | 1085 Raymond Blvd. | 14th Floor | Newark, NJ | 07102
T: 973-792-1710 | M: 201-314-7177 | dkilinski@dhrinternational.com
 
 
 

 

 
About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltration (HDF) system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products, which includes the MSU and SSU ultrafilters. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. The Nephros DSU, MSU, and SSU are FDA cleared for the filtration of biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.  Nephros’ DSU ultrafilters are being evaluated at several major U.S. medical centers for infection control. Nephros ultrafilter technology has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros’ control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to continue as a going concern; (ii) to realize the benefit of any strategic relationship, including the license agreement with Bellco, the joint collaboration agreement with STERIS Corporation and projects with the U.S. military; (iii) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (iv) to obtain additional funding when needed or on favorable terms; v) to have its technologies and products accepted in current or future target markets; (vi) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; or (vii) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros’ filings with the SEC. Investors and security holders are encouraged to read these documents on the SEC's website at http://www.sec.gov/. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.